ARMGO® Partnerships

   
 

March 22, 2006 Columbia University License

  ARMGO Pharma, Inc., has obtained an exclusive, worldwide license from Columbia University to the groundbreaking ryanodine receptor technology discovered by the company‚Äôs scientific founder, Dr Andrew R. Marks. This technology is forming the basis of our discovery and development efforts for cardiac heart failure therapeutics and various other cardiac disorders and are also being developed for skeletal muscle disorder and related diseases. The license includes a strong patent estate for the core technology, significant know-how possessed by Dr Marks and his team, and a series of hits and leads which have been shown to be active in in vitro and in vivo models.
   
 

March 22, 2006 Servier Collaborative Partnership

  ARMGO Pharma, Inc. has granted an exclusive worldwide (excluding US and Japan) sublicense to Servier, a privately held French pharmaceutical firm, to the ryanodine receptor technology for the cardiovascular field.
   
 

June 11, 2007 Servier Collaborative Partnership

  ARMGO Pharma, Inc. has granted an exclusive worldwide (excluding US and Japan) sublicense to Servier, a privately held French pharmaceutical firm, to the ryanodine receptor technology for muscle indications.
   

Current News



 

ARMGO Pharma Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for ARM210/S48168 for the Treatment of Duchenne Muscular Dystrophy   Link to Article


 

ARMGO Pharma and Servier Announce Advancement of Rycal ARM210/S48168 into Clinical Stage Program Targeting Duchenne Muscular Dystrophy   Link to Article


 

ARMGO Pharma Receives Research Grant Award from Kennedy's Disease Association to Support Advancement of Rycal Compounds   Link to Article


 

ARMGO Pharma Receives $1 Million Award from MDA to Support Advancement of Rycal Compound ARM210 as a Novel Treatment for Duchenne Muscular Dystrophy   Link to Article


 

ARMGO Pharma, Inc. announces the appointment of Dr. Sapan Shah as CEO   Link to Article


 

Kushnir A, Marks AR. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol. 2010;59:1-30.   Link to Article


 

Kushnir A, Shan J, Betzenhauser MJ, Reiken S, Marks AR. Role of CaMKlldelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. Proc Natl Acad Sci U S A. 2010 Jun1;107(22):10274-9.   Link to Article


 

Kushnir A, Betzenhauser MJ, Marks AR. Ryanodine receptor studies using genetically engineered mice.FEBS Lett. 2010 May 17;584(10):1956-65.   Link to Article


 

Betzenhauser MJ, Marks AR. Ryanodine Receptor channelopathies Pflugers Arch. 2010 Jul;460(2):467-80.   Link to Article


 

Fauconnier J, Thireau J, Reiken S, Cassan C, Richard S, Matecki S, Marks AR,Lacampagne A.- Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy.Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1559-64.4-9.   Link to Article


Prof. Andrew Marks presentation on, "Mechanism-Based Therapies for Heart Failure and Cardiac Arrhythmias" from the Henry Stewart Talks, Series, "Calcium Signalling: Regulation, Mechanisms, Effectors, Role in Disease and Recent Advances".
Link to Presentation